Cargando…

PCSK9 targets important for lipid metabolism

Ischemic heart disease is the main cause of death worldwide and it is accelerated by increased low-density lipoprotein (LDL) cholesterol (LDL-C) and/or lipoprotein (a) (Lp(a)) concentrations. Proprotein convertase subtilisin/kexin type 9 (PCSK9) alters both LDL-C and in part Lp(a) concentrations thr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schulz, Rainer, Schlüter, Klaus-Dieter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5352789/ https://www.ncbi.nlm.nih.gov/pubmed/28176216 http://dx.doi.org/10.1007/s11789-017-0085-0

Ejemplares similares

Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
por: Schulz, Rainer, et al.
Publicado: (2015)

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
por: Glerup, Simon, et al.
Publicado: (2017)

PCSK9 in Myocardial Infarction and Cardioprotection: Importance of Lipid Metabolism and Inflammation
por: Andreadou, Ioanna, et al.
Publicado: (2020)

Autocrine effects of PCSK9 on cardiomyocytes
por: Wolf, Annemarie, et al.
Publicado: (2020)

Editorial: PCSK9: Importance in Physiology and Pathophysiology
por: Schulz, Rainer, et al.
Publicado: (2021)

Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Deletion but Not Inhibition of Extracellular PCSK9 Reduces Infarct Sizes Ex Vivo but Not In Vivo
por: Schreckenberg, Rolf, et al.
Publicado: (2022)

Oxidized low-density lipoprotein (oxLDL) affects load-free cell shortening of cardiomyocytes in a proprotein convertase subtilisin/kexin 9 (PCSK9)-dependent way
por: Schlüter, Klaus-Dieter, et al.
Publicado: (2017)

Rewiring Lipid Metabolism by Targeting PCSK9 and HMGCR to Treat Liver Cancer
por: Alannan, Malak, et al.
Publicado: (2022)

Importance of Mitochondria in Cardiac Pathologies: Focus on Uncoupling Proteins and Monoamine Oxidases
por: Schulz, Rainer, et al.
Publicado: (2023)

Impact of PCSK9 on CTRP9-Induced Metabolic Effects in Adult Rat Cardiomyocytes
por: Rohrbach, Susanne, et al.
Publicado: (2021)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
por: Alannan, Malak, et al.
Publicado: (2022)

Untypical Metabolic Adaptations in Spontaneously Hypertensive Rats to Free Running Wheel Activity Includes Uncoupling Protein-3 (UCP-3) and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Expression
por: Wolf, Annemarie, et al.
Publicado: (2021)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Lipid Lowering Therapy and Circulating PCSK9 Concentration
por: Nozue, Tsuyoshi
Publicado: (2017)

Phage display for targeting PCSK9
por: Ferri, Nicola
Publicado: (2021)

Gene Therapy Targeting PCSK9
por: Katzmann, Julius L., et al.
Publicado: (2022)

PCSK9 and triglyceride-rich lipoprotein metabolism
por: Druce, Irena, et al.
Publicado: (2015)

PCSK9 signaling pathways and their potential importance in clinical practice
por: Wiciński, Michał, et al.
Publicado: (2017)

Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations
por: Mayne, Janice, et al.
Publicado: (2013)

Serum PCSK9 levels, but not PCSK9 polymorphisms, are associated with CAD risk and lipid profiles in southern Chinese Han population
por: Cai, Gaojun, et al.
Publicado: (2018)

Role of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) on Lipid Metabolism and Insulin Resistance in Human
por: Muraki, Isao
Publicado: (2021)

Ginkgolide B Mediated Alleviation of Inflammatory Cascades and Altered Lipid Metabolism in HUVECs via Targeting PCSK-9 Expression and Functionality
por: Wang, Gang, et al.
Publicado: (2019)

Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
por: Kosmas, Constantine E, et al.
Publicado: (2017)

PCSK9: A Potential Therapeutic Target for Sepsis
por: Yuan, Yuan, et al.
Publicado: (2020)

PCSK9 inhibitors: A new era of lipid lowering therapy
por: Chaudhary, Rahul, et al.
Publicado: (2017)

PCSK9 and Calcific Aortic Valve Stenosis: Moving Beyond Lipids
por: Leopold, Jane A.
Publicado: (2020)

Non-Lipid Effects of PCSK9 Monoclonal Antibodies on Vessel Wall
por: Ugovšek, Sabina, et al.
Publicado: (2022)

PCSK9 as a therapeutic target for cardiovascular disease
por: Zhang, Pei-Ying
Publicado: (2017)

Lipid Target in Very High-Risk Cardiovascular Patients: Lesson from PCSK9 Monoclonal Antibodies
por: Ciccarelli, Giovanni, et al.
Publicado: (2018)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Targeting PCSK9 in Liver Cancer Cells Triggers Metabolic Exhaustion and Cell Death by Ferroptosis
por: Alannan, Malak, et al.
Publicado: (2022)

PCSK9 and carbohydrate metabolism: A double-edged sword
por: Filippatos, Theodosios D, et al.
Publicado: (2017)

The AAV-PCSK9 murine model of atherosclerosis and metabolic dysfunction
por: Keeter, William Coles, et al.
Publicado: (2022)

PCSK9: The Nexus of Lipoprotein Metabolism and Inflammation in COVID-19
por: Goonewardena, Sascha N., et al.
Publicado: (2023)

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

Effects of PCSK9 Targeting: Alleviating Oxidation, Inflammation, and Atherosclerosis
por: Punch, Emily, et al.
Publicado: (2022)

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans
por: Reyes-Soffer, Gissette, et al.
Publicado: (2017)

Interplay between microRNAs, Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), and Lipid Parameters in Patients with Very High Lipoprotein(a) Treated with PCSK9 Inhibitors
por: Levstek, Tina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_av99objblaj31po9h8lrsvapod